Brain Cancer Trial, Recruiting NCT05868928 Sponsor: Asan Medical Center Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT05868928
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had a type of precise brain radiation treatment called stereotactic radiosurgery (SRS — including Gamma Knife or CyberKnife) for cancer that has spread to the brain
  • People with between one and ten newly diagnosed brain tumours that are suitable for this type of radiation treatment
  • People who are not currently experiencing sudden or severe neurological symptoms (such as sudden weakness, seizures, or loss of speech)
  • People who score 70 or higher on a standard health and functioning scale called the Karnofsky Performance Status (confirm with trial site for exact details)
  • People who have had a brain MRI scan within one month before joining the trial
  • People whose brain tumours show clear, measurable areas of enhancement (visible change) on an MRI scan
  • People for whom follow-up imaging or a second surgical procedure is available to help confirm how the tumour has changed over time
  • People whose largest tumour measures more than 1.5 cm at its widest point

Who may not be able to join:

  • People who have previously had brain surgery, stereotactic radiosurgery, or whole-brain radiation therapy
  • People diagnosed with certain cancer types, including leukaemia, lymphoma, germ cell tumours, small-cell lung cancer, cancer spread along the lining of the brain (leptomeningeal disease), or cancer of unknown origin
  • People under 18 years of age
  • People who do not have a baseline (starting point) MRI scan available
  • People whose brain tumours cannot be clearly measured on MRI — including tumours smaller than 10 mm, tumours with unclear borders, or tumours located on the lining of the brain, the bones of the skull, or along the brain's lining (leptomeningeal disease)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ho Sung Kim, MD, PhD, Asan Medical Center

Phone: +82230105682

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 December 2023
Est. completion
30 July 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Time to progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov